Treatment 2.0 Pilot in Vietnam—Early Progress and Challenges


Announced in 2010 at the International AIDS Conference in Vienna and pioneered by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization's (WHO) leadership at the global level, Treatment 2.0 is a new approach to the HIV response that encourages innovation, efficiency, and sustainability. Building upon WHO and UNAIDS' "3 by 5" Initiative, Treatment 2.0 focuses upon scale-up and universal access of life-saving ART treatment through strategic investments and innovations in five priority pillars that include: 1) Optimize drug regimens, 2) Provide point-of-care (POC) and other simplified diagnostic and monitoring tools, 3) Reduce costs, 4) Adapt service delivery, and 5) Mobilize communities [1-3]. The Treatment 2.0 approach is in line with UNAIDS' 2011-2015 Strategy: Getting to Zero with the vision of, "Zero New infections; Zero discrimination; and Zero AIDS-related deaths", and as well as the four strategic directions for the health sector response outlined under WHO's Global Health Sector Strategy on HIV/AIDS 2011-2015 [4,5]. At the Sixty-fourth World Health Assembly (WHA) in May 2011, it was formally announced that Vietnam has taken the leadership to pilot Treatment 2.0 in two of its provinces, with support from both the WHO and UNAIDS country offices [6,7]. Given that Vietnam is one of the few countries with a concentrated epidemic to pilot Treatment 2.0, the outcomes and experiences of this initiative can provide valuable insight to other countries who may consider implementation. The objectives of this article are therefore to: 1) Describe the early process for translating Treatment 2.0 concept in Vietnam's context; and 2) Highlight early progress and challenges.

Share and Cite:

D. Duong Bui, F. Mesquita, T. Nhan Do, M. Kato, T. Van Nguyen, T. Thu Nguyen and A. Poon, "Treatment 2.0 Pilot in Vietnam—Early Progress and Challenges," World Journal of AIDS, Vol. 2 No. 2, 2012, pp. 64-70. doi: 10.4236/wja.2012.22009.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] World Health Organization, Joint United Nations Programe on HIV/AIDS, “The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support,” Geneva, 2011.
[2] G. Hirnschall and B. Schwartlander, “Treatment 2.0: Catalysing the Next Phase of Scale-Up,” The Lancet, Vol. 378, No. 9787, 2011, pp. 209-211. doi:10.1016/S0140-6736(11)60247-X
[3] B. Schwartlander, J. Stover, T. Hallett, R. Atun, C. Avila, E. Gouws, et al., “Towards an Improved Investment Approach for an Effective Response to HIV/AIDS,” The Lancet, Vol. 377, 9782, 2011, pp. 2031-2041. doi:10.1016/S0140-6736(11)60702-2
[4] World Health Organization, et al., “Global Health Sector Strategy on HIV/AIDS 2011-2015,” Geneva, 2011.
[5] Joint United Nations Programme on HIV/AIDS, “UNAIDS 2011-2015 Strategy: Getting to Zero,” Geneva, 2010.
[6] World Health Organization, “WHO HIV Strategy: Implementing Treatment 2.0, Side Event at the Sixty-Fourth World Health Assembly,” Geneva, 2011.
[7] Joint United Nations Programme on HIV/AIDS, World Health Organization, “Vietnam Leads on Treatment 2.0—First Pilot Begins in Mid-2011,” Hanoi, 2011.
[8] Ministry of Health, “20 Years: Responding to HIV/AIDS in Vietnam,” Hanoi, 2010.
[9] L. Maher, H. Coupland and R. Musson, “Scaling up HIV Treatment, Care and Support for Injecting Drug Users in Vietnam,” International Journal of Drug Policy, Vol. 18, No. 4, 2007, pp. 296-305. doi:10.1016/j.drugpo.2006.12.006
[10] V. Van Tam, A. Pharris, A. Thorson, T. Alfven and M. Larsson, “It Is Not that I Forget, It’s just that I don’t Want Other People to Know: Barriers to and Strategies for Adherence to Antiretroviral Therapy among HIV Patients in Northern Vietnam,” AIDS Care, Vol. 23, No. 2, 2011, pp. 139-145. doi:10.1080/09540121.2010.507741
[11] A. D. Ngo, E. A. Ratliff, S. A. McCurdy, M. W. Ross, C. Markham and H. T. Pham, “Health-seeking Behaviour for Sexually Transmitted Infections and HIV Testing among Female Sex Workers in Vietnam,” AIDS Care, Vol. 19, No. 7, 2007, pp. 878-887. doi:10.1080/09540120601163078
[12] World Health Organization, “Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach,” Geneva, 2010.
[13] Vietnam Administration of HIV/AIDS Control, Pasteur Institute of Ho Chi Minh City, “Organization WH. Preliminary Results of HIV/AIDS Care and Treatment and Early Warning Indicators of HIV Drug Resistance, Southern Vietnam, 2010,” Ho Chi Minh City, 2011.
[14] R. Subbaraman, S. K. Chaguturu, K. H. Mayer, T. P. Flanigan and N. Kumarasamy, “Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries,” Clinical Infectious Diseases, Vol. 45, No. 8, 2007, pp. 1093-1101. doi:10.1086/521150
[15] G. McComsey and J. T. Lonergan, “Mitochondrial dysfunction: Patient Monitoring and Toxicity Management,” Journal of Acquired Immune Deficiency Syndromes, Vol. 37, Suppl. 1, 2004, pp. S30-S35. doi:10.1097/01.qai.0000137004.63376.27
[16] T. A. Nguyen, H. T. Nguyen, G. T. Le and R. Detels, “Prevalence and Risk Factors Associated with HIV Infection among Men Having Sex with Men in Ho Chi Minh City, Vietnam,” AIDS and Behavior, Vol. 12, No. 3, 2008, pp. 476-482. doi:10.1007/s10461-007-9267-y
[17] V. F. Go, C. Frangakis, L. Van Nam, T. Sripaipan, A. Bergenstrom, F. Li, et al., “Characteristics of High-Risk HIV-Positive IDUs in Vietnam: Implications for Future Interventions,” Substance Use & Misuse, Vol. 46, No. 4, 2011, pp. 381-389. doi:10.3109/10826084.2010.505147
[18] M. S. Cohen, Y. Q. Chen, M. McCauley, T. Gamble, M. C. Hosseinipour, N. Kumarasamy, et al., “Prevention of HIV-1 Infection with Early Antiretroviral Therapy,” The New England Journal of Medicine, Vol. 365, No. 6, 2011, pp. 493-505. doi:10.1056/NEJMoa1105243

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.